In a bleomycin-induced pulmonary fibrosis rat model, epalrestat (an AR inhibitor) reduced fibrosis changes in the lung and prevented collagen deposition by decreasing expression and production of TGFβ1, α-smooth muscle actin (α-SMA), and type I collagen [126]. Here, TGFB1 is linked to pulmonary fibrosis.